Colorectal Cancer - Healing Genes

Colorectal Cancer

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

DC Vaccine in Colorectal Cancer

Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer

Phase 1


Researchers at the University of Pennsylvania are piloting a study of a dendritic cell (DC) vaccine for colorectal cancer. DCs are rare immune cells that are unique in their ability to tell other immune cells, T-cells, to seek out tumors and attack them. The treatment will use the patient’s own DCs to multiply and prepare them to recognize their cancer in a lab before returning them to the patient via 2 IV injections. Prior to that infusion, a chemotherapy dosage will be required. Follow up continues at regular clinic visits for approximately 1 year following the final vaccine.


  • Be 18 years of age and older
  • Meet cancer screening requirements specific to the study
  • Not be pregnant or breastfeeding


  1. Screening before the treatment
  2. A course of chemotherapy prior to first vaccine injection
  3. 2 injections of the vaccine therapy drug will be administered 8 weeks apart
  4. Monitoring of the patient during treatment, then follow up for 1 year.


The study location is at the University of Pennsylvania in Philadelphia, PA. Map.

Contact: Emerging Medicine  |  855.216.0098  |  [email protected]


University of Pennsylvania


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader